Patient-reported symptoms and HRQL of MF and SS patients receiving mogamulizumab over 24 weeks: interim results from the PROSPER study
Authors
Scarisbrick, J.Arumainathan, A.
Cowan, Richard
DeSimone, J.
Esler, C.
Geskin, L. J.
Goldaniga, M.
Violetti, S. A.
Mheidly, K.
Morsia, E.
Muniesa, C.
Musiek, A.
Nassi, L.
Pagano, L.
Pileri, A.
Pujol, R. M.
Quint, K.
Rozati, S.
Sandilands, K.
Shinohara, M.
Williams, A.
Teoli, M.
Affiliation
Christie Hospital Foundation NHS Trust, University of Manchester, Manchester, United KingdomIssue Date
2024
Metadata
Show full item recordCitation
Scarisbrick J, Arumainathan A, Cowan R, DeSimone J, Esler C, Geskin LJ, et al. Patient-reported symptoms and HRQL of MF and SS patients receiving mogamulizumab over 24 weeks: interim results from the PROSPER study. EUROPEAN JOURNAL OF CANCER. 2024 OCT;211:S61-S2. PubMed PMID: WOS:001330761900121. English.Journal
European Journal of CancerDOI
10.1016/j.ejca.2024.114459Additional Links
https://dx.doi.org/10.1016/j.ejca.2024.114459Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2024.114459